Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15551041 | 0.92 | BACE1 (0.64) | BACE1 | |
| SCHEMBL15589208 | 0.84 | BACE1 (0.55) | BACE1KCNH2 | |
| SCHEMBL15817189 | 0.83 | BACE1 (0.65) | BACE1KCNH2 | |
| SCHEMBL15551038 | 0.81 | BACE1 (0.57) | BACE1KCNH2 | |
| SCHEMBL15550466 | 0.80 | BACE1 (0.40) | BACE1KCNH2 | |
| SCHEMBL15550146 | 0.78 | BACE1 (1.00) | BACE1KCNH2 | |
| SCHEMBL15549238 | 0.78 | BACE1 (0.68) | BACE1 | |
| SCHEMBL15816754 | 0.78 | BACE1 (0.52) | BACE1KCNH2 | |
| SCHEMBL15550010 | 0.77 | BACE1 (0.65) | BACE1KCNH2 | |
| SCHEMBL15817845 | 0.77 | BACE1 (0.67) | BACE1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242973-B2 | Chromane compounds | COMENTIS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150225386-A1 | CHROMANE COMPOUNDS | COMENTIS, INC. | 2015-08-13 | — | — | US | disclosed |
| EP-2854797-A2 | CHROMANE COMPOUNDS | Comentis, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8975415-B2 | Chromane compounds | COMENTIS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140179695-A1 | CHROMANE COMPOUNDS | COMENTIS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2013181202-A2 | CHROMANE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179695-A1 | CHROMANE COMPOUNDS | BACE1, BACE2, APP | BACE1 1/4885KCNH2 4425/4885 |
| US-20150225386-A1 | CHROMANE COMPOUNDS | BACE1, BACE2, APP | BACE1 1/4885KCNH2 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.